Accretion/Dilution Calculator

The choice of financing is one of the most powerful levers in determining whether an M&A deal is accretive or dilutive. Each form of consideration has a different cost, and the optimal mix depends on the relative valuations of the acquirer and target, prevailing interest rates, and the acquirer's balance sheet capacity.

Cash consideration:

• Cost — The acquirer gives up the after-tax interest income it would have earned on that cash (the "foregone interest" or opportunity cost). At a 4% risk-free rate and 25% tax rate, $1 billion in cash costs roughly $30M in lost after-tax income per year.
• Advantage — No new shares are issued, so there is no share dilution. Cash deals tend to be more accretive when interest rates are low because the opportunity cost of deploying cash is minimal.
• Disadvantage — Depletes the balance sheet, reducing financial flexibility. Large all-cash deals may require the acquirer to raise debt anyway.

Stock consideration:

• Cost — New shares are issued to target shareholders, diluting existing shareholders' ownership. The more shares issued, the larger the denominator in the EPS calculation.
• Key factor: P/E comparison — If the acquirer's P/E ratio is higher than the implied P/E paid for the target (offer price / target EPS), a stock deal tends to be accretive. If the acquirer's P/E is lower, the deal is likely dilutive because the acquirer is issuing "expensive" shares (relative to its earnings) to buy "cheaper" earnings.
• Advantage — Preserves cash and balance sheet capacity. Stock deals also allow target shareholders to participate in combined upside.

Debt consideration:

• Cost — After-tax interest expense on the newly raised debt. At 5% pre-tax cost and 25% tax rate, each $1 billion in debt costs $37.5M in after-tax interest per year.
• Advantage — No share dilution (like cash), and debt interest is tax-deductible, making it cheaper than equity on an after-tax basis.
• Disadvantage — Increases leverage, which may affect credit ratings and financial flexibility. Too much acquisition debt can spook rating agencies and increase the acquirer's borrowing costs across the board.

The bottom line: As a rule of thumb, cash and debt deals are more likely to be accretive (but add financial risk), while stock deals are more likely to be dilutive (but preserve flexibility). The sensitivity table in this calculator lets you compare all scenarios side by side.

Breakeven synergies represent the minimum amount of pre-tax annual synergies (cost savings and/or revenue enhancements) that the combined company must achieve for the deal to be EPS-neutral — meaning the acquirer's pro forma EPS equals its standalone EPS. If realized synergies exceed this breakeven threshold, the deal becomes accretive; if they fall short, it remains dilutive.

The formula:

• Start with the condition: pro forma EPS = acquirer standalone EPS.
• Pro forma EPS = (acquirer NI + target NI + synergies × (1 - tax rate) - financing costs) / pro forma shares.
• Set this equal to acquirer standalone EPS and solve for synergies. The result is the minimum pre-tax synergies needed to bridge the gap.

Why breakeven synergies matter:

• Board-level decision tool — When a board evaluates a deal, they ask: "How much in synergies do we need to justify this price?" If the breakeven is $50M and the integration team is confident they can deliver $200M, the deal has a wide margin of safety.
• Negotiation leverage — If the breakeven synergies are very high relative to what's realistically achievable, the acquirer may need to negotiate a lower offer price, change the financing mix, or walk away.
• Risk assessment — Deals that require large synergies to break even are inherently riskier because synergies often take longer to realize than management projects, and some announced synergies never fully materialize.

Types of synergies:

• Cost synergies — Eliminating duplicate functions (corporate headquarters, back-office, overlapping sales teams), renegotiating supplier contracts with greater purchasing power, consolidating facilities. These are easier to quantify and more reliable.
• Revenue synergies — Cross-selling products to each other's customer bases, entering new markets together, or combining R&D capabilities. These are harder to achieve and Wall Street typically discounts them heavily.

Rule of thumb: If breakeven synergies exceed 5-10% of the target's revenue, the deal is probably overpriced. Most successful acquisitions have achievable synergies well below this threshold.

A deal is dilutive to EPS when the pro forma earnings per share (after combining the acquirer and target) is lower than the acquirer's standalone EPS. This happens when the cost of the consideration (interest expense on debt, foregone interest on cash, or share dilution from stock) outweighs the earnings contribution from the target plus any synergies.

Common causes of dilution:

• Paying too high a premium — The higher the offer price relative to the target's earnings, the more the deal costs the acquirer. A deal at 30x the target's P/E is much harder to make accretive than one at 15x.
• Using stock when the acquirer's P/E is lower — If the acquirer trades at 15x P/E and pays 25x for the target with stock, the acquirer is essentially exchanging its expensive earnings for cheaper earnings.
• Insufficient synergies — When the financing cost of the deal exceeds the target's earnings contribution, only synergies can bridge the gap. If synergies are too small, dilution persists.
• High interest rates — When debt is expensive, debt-financed deals have a higher financing cost, making accretion harder to achieve.

Is dilution always bad? No. Dilution is a first-year measure, and some of the best acquisitions in corporate history were initially dilutive:

• Growth acquisitions — Buying a high-growth company that currently has low earnings but significant future potential will be dilutive today but may be massively accretive in 2-3 years as the target's earnings ramp up.
• Strategic transformations — A deal that repositions the acquirer into a higher-growth or higher-multiple sector can create enormous shareholder value even if it's dilutive on day one.
• Platform acquisitions — An initially dilutive deal that enables a series of highly accretive bolt-on acquisitions can create value over a multi-year horizon.

The market's reaction: While accretion is preferred, sophisticated investors look beyond first-year EPS impact. They evaluate the strategic rationale, synergy credibility, integration risk, and whether management has a track record of delivering on acquisition promises. A well-explained dilutive deal can be rewarded; a poorly explained accretive deal can still tank the stock.

Accretion/dilution analysis is a core deliverable in virtually every M&A transaction. Investment bankers build this analysis into pitch books, board presentations, fairness opinions, and merger proxy statements. Here is how it fits into the transaction process at each stage.

1. Early-stage pitching

• When an IB team pitches a potential acquisition to a client, they include a preliminary accretion/dilution analysis showing the EPS impact at various offer prices and financing structures. This helps the client's board decide whether to pursue the deal.
• The analysis is typically presented as a matrix: offer price on one axis, financing mix on the other, with accretion/dilution percentages in each cell.

2. Deal negotiation

• During negotiations, bankers update the analysis in real time as offer terms change. If the target pushes for a higher price, the banker shows the board how much more in synergies would be needed to keep the deal accretive.
• The breakeven synergies number becomes a critical negotiation anchor — it sets the maximum price the acquirer should rationally pay given realistic synergy assumptions.

3. Board approval and fairness opinions

• The final accretion/dilution analysis is a required exhibit in the board's package when voting to approve the transaction. Directors need to understand the EPS impact to fulfill their fiduciary duties.
• Fairness opinion letters from the financial advisor reference the accretion/dilution analysis as one of several methodologies used to evaluate the deal's fairness.

4. Merger proxy and investor communication

• After the deal is announced, the merger proxy (the document sent to shareholders for a vote) includes the accretion/dilution analysis. Shareholders evaluate whether the EPS impact justifies their vote in favor of the deal.
• Management teams reference accretion in earnings calls and investor presentations to build support for the transaction.

Interview context: In IB interviews, you will almost certainly be asked to walk through an accretion/dilution analysis. The most common questions are: "When is a deal accretive?" (when the target's P/E is below the acquirer's in an all-stock deal), "How do synergies affect the analysis?" (they increase pro forma NI and improve accretion), and "Walk me through the full calculation" (which this calculator does automatically).

The relationship between the acquirer's P/E ratio and the effective P/E paid for the target is the single most important driver of whether an all-stock deal is accretive or dilutive. Understanding this relationship is the fastest way to build intuition for M&A EPS impact.

The P/E rule for all-stock deals:

• Acquirer P/E > target P/E paid — The deal is accretive. The acquirer is issuing shares that trade at a higher earnings multiple than the earnings it is acquiring. Each new share issued "buys" more earnings than it costs, improving EPS.
• Acquirer P/E < target P/E paid — The deal is dilutive. The acquirer is giving away "expensive" shares (high earnings per share) to buy "expensive" earnings (low earnings per dollar of price paid). This reduces EPS.
• Acquirer P/E = target P/E paid — The deal is EPS-neutral before synergies.

Example: If the acquirer trades at 20x P/E ($70 price / $3.50 EPS) and offers to buy the target at an implied 25x P/E ($50 offer / $2.00 EPS), the acquirer is paying a higher multiple for the target's earnings than its own market gives it. This is inherently dilutive in a stock deal.

Why this matters for premium analysis: The target's standalone P/E (based on its trading price before the deal) is often lower than the implied P/E at the offer price, because the acquirer is paying a premium to gain control. This premium is the main source of dilution. The synergies must be large enough to offset the premium's dilutive effect.

Cash and debt deals are different: In a cash or debt deal, the P/E comparison is between the target's earnings yield (target EPS / offer price) and the after-tax cost of the cash or debt. If the target's earnings yield exceeds the after-tax financing cost, the deal is accretive. This is why cash deals are often more accretive than stock deals — the opportunity cost of cash (foregone interest) is typically much lower than the acquirer's earnings yield.

Synergies are the additional value created by combining two companies that neither company could achieve independently. They are the primary justification for paying a premium over the target's standalone value, and they are the variable that most often determines whether a deal is accretive or dilutive.

Types of synergies:

• Cost synergies (more reliable) — Eliminating redundant corporate overhead (dual headquarters, back-office functions), consolidating manufacturing or distribution facilities, renegotiating supplier contracts at scale, and reducing overlapping R&D spending. Cost synergies are the most credible because they are within management's control.
• Revenue synergies (less reliable) — Cross-selling products to each other's customer bases, bundling complementary products, geographic expansion using the other company's distribution network, or combined pricing power. Revenue synergies are harder to achieve because they depend on customer behavior and market dynamics.
• Financial synergies — Tax benefits (using the target's NOLs), lower borrowing costs due to larger scale, or improved working capital efficiency. These are real but often smaller in magnitude.

How Wall Street values synergies:

• Analysts typically apply a "synergy haircut" of 25-50% to management's estimates. If management claims $500M in synergies, the market may only give credit for $250-375M.
• Cost synergies are credited at near face value; revenue synergies are often discounted by 50-75% or ignored entirely.
• Timeline matters — Most synergies take 2-3 years to fully realize. Year-one synergies are typically only 30-50% of the ultimate run-rate.
• Integration costs (severance, IT migration, facility closures) partially offset synergies in the first 1-2 years.

For this calculator: Enter your estimated pre-tax annual synergies at full run-rate. The calculator applies the tax rate to convert them to after-tax synergies, which is what flows into the pro forma income statement. Remember that this is a simplified first-year analysis — in practice, synergies phase in over multiple years.

M&A history provides plenty of examples that illustrate accretion/dilution dynamics. These real-world cases show why the math matters and why first-year EPS impact alone is not the full picture.

Examples of accretive deals:

• Large-cap "bolt-on" acquisitions — When a high-P/E acquirer buys a smaller, lower-P/E company using stock, the deal is almost automatically accretive. This is why large tech and pharma companies with high multiples can be serial acquirers — their currency (stock) is valued richly enough that acquiring almost any profitable target improves EPS.
• Cash-rich companies in low-rate environments — When cash earns near-zero interest, deploying that cash to buy an earnings-generating business is almost always accretive because the opportunity cost of the cash is negligible.

Examples of dilutive deals:

• Transformative growth acquisitions — When a slow-growth company buys a high-growth, high-P/E target, the deal is typically dilutive in year one. The acquirer is paying a premium for future growth that has not yet materialized in earnings.
• Mega-mergers with large premiums — Deals involving 40-60% premiums to the target's trading price are often dilutive because the premium inflates the effective P/E being paid. These deals require massive synergies to justify.

The key takeaway: Accretion/dilution is a necessary but insufficient analysis. It tells you about first-year EPS impact, but it says nothing about long-term strategic value, integration risk, or whether the combined company will be worth more than the sum of its parts. The best M&A analysis combines accretion/dilution with DCF valuation, comparable company analysis, and a thorough assessment of strategic fit and synergy achievability.